Author

S. Dong

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Pseudoprogression in neoadjuvant immunotherapy for resectable NSCLC: a PET–CT-based study

Background Neoadjuvant chemoimmunotherapy is standard for resectable non-small-cell lung cancer (NSCLC) but response assessment is challenging due to pseudoprogression, which may lead to unnecessary cancellation of surgery. We characterized pseudoprogression and developed a clinical strategy to distinguish it from true...

Y. Pan, J. Chen, H. Lin et al. · ESMO Open · 0 citations

Oct 2026

PRODH promotes osimertinib drug-tolerant persistence in EGFR-mutant NSCLC by activating mitochondrial transcription.

The emergence of drug-tolerant persister (DTP) cells poses a major obstacle to durable responses to EGFR tyrosine kinase inhibitors (TKIs) in EGFR-mutant non-small cell lung cancer (NSCLC). However, how metabolic programming orchestrates this transient and reversible adaptive resistance remains largely unexplored. Here...

Xiang Meng, Liang Chen, Yu-Qing Yang et al. · Cancer Letters · 0 citations